Sandoz Forms Insulin Biosimilars Deal With Gan & Lee

In line with its strategy to expand its biosimilars business, Sandoz has entered into an agreement with China’s Gan & Lee to market and supply three insulin biosimilars in the EU, US, and other key territories.

Diabetes
Sandoz will extend access to diabetes treatments through insulins deal • Source: Shutterstock

More from Biosimilars

More from Products